Clinical Trials in Jinzhou, China
3 recruiting
Showing 1–14 of 14 trials
Recruiting
Phase 3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Cardiovascular DiseasesHypertensionDiabetes Mellitus, Type 2
Boehringer Ingelheim11,800 enrolled1152 locationsNCT07064473
Recruiting
Phase 3
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Colorectal Neoplasms
Seagen, a wholly owned subsidiary of Pfizer400 enrolled382 locationsNCT05253651
Recruiting
Phase 3
A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
HER2-positive Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.544 enrolled78 locationsNCT07043725
Recruiting
Phase 2
Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.134 enrolled32 locationsNCT06897579
Recruiting
A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular Disease
Major Cardiovascular EventEstablished Atherosclerotic Cardiovascular Disease
Amgen7,000 enrolled90 locationsNCT06295679
Recruiting
Phase 2
A Study to Evaluate 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease (COPD)
Mabwell (Shanghai) Bioscience Co., Ltd.360 enrolled51 locationsNCT07292714
Recruiting
Phase 1Phase 2
A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors
Advanced Cancer
Suzhou Transcenta Therapeutics Co., Ltd.320 enrolled40 locationsNCT04495296
Recruiting
Phase 3
A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)
Locally Advanced or Metastatic Breast Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd.460 enrolled60 locationsNCT06680921
Recruiting
Phase 3
Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke (SHINY)
Ischemic Stroke, Acute
Beijing Tiantan Hospital1,380 enrolled82 locationsNCT06157502
Recruiting
Phase 3
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Breast Cancer (Early Breast Cancer)
AstraZeneca5,500 enrolled794 locationsNCT05952557
Recruiting
Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)
Non-small Cell Lung Cancer
Daiichi Sankyo150 enrolled23 locationsNCT06809764
Recruiting
Early Phase 1
Safety and Efficacy of PRG-2302 for Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia Disease.
Acute Lymphoblastic Leukemia
Tan Jie18 enrolled1 locationNCT06659653
Recruiting
Huaier Granules for Prevention of Recurrence and Metastasis of Colorectal Cancer Patients Following Radical Surgery
Colorectal, Cancer
Xi Shan Wang3,060 enrolled22 locationsNCT03349762
Recruiting
Phase 3
Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
Hepatocellular Carcinoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.480 enrolled67 locationsNCT05862337